国元证券研究报告

Group 1: Company Performance and Market Position - 和誉-B has a total market value of 88 million HKD and a recent price of 12.90 HKD, with a year-to-date increase of 199.3% since its inclusion on November 1, 2024[3] - 宜明昂科-B has a market value of 27 million HKD, with a recent price of 6.17 HKD, showing a decline of 10.7% since its inclusion on April 2, 2025[3] - 石药集团 has a market value of 987 million HKD, with a recent price of 8.57 HKD, and is expected to recover quickly post-2025 as key innovative drugs are launched[3] Group 2: Financial Metrics and Projections - 和誉-B's EPS for 2024 is projected at 0.04 HKD, with a PE ratio of 298.65 and a PB ratio of 86.00[3] - 宜明昂科-B's EPS for 2025E is projected at -0.91 HKD, with a PE ratio of -10.28 and a PB ratio of 3.63[3] - 石药集团's EPS for 2024 is projected at 0.40 HKD, with a PE ratio of 21.52 and a PB ratio of 2.83[3] Group 3: Strategic Developments - 和誉-B has signed a licensing agreement with Merck for exclusive commercialization rights in Greater China, with a total agreement value of 605.5 million USD, including a 70 million USD upfront payment[3] - 猎豹移动's AI business revenue has increased by approximately 100% year-on-year, indicating strong market demand and commercialization capabilities[3] - 阿里巴巴 is focusing on high CAPEX investments in AI and cloud services, with a market value of 27,354 million HKD and a recent price of 143.30 HKD, expected to enhance revenue growth[3]